The goal of this observational study is to investigate DNA methylation changes in adults with bleeding from brain aneurysm, which is called aneurysmal subarachnoid hemorrhage (aSAH), and their association with delayed ischemic neurologic deficit (DIND). The main questions it aims to answer are: Are there specific DNA methylation changes in peripheral blood that differentiate patients with aSAH from healthy individuals? Can DNA methylation changes in peripheral blood predict the development of DIND following aSAH? Researchers will compare blood DNA methylation profiles of aSAH patients to healthy controls and also do subgroup analysis of patients with DIND versus those without DIND to see if there are distinct methylation patterns associated with aSAH and DIND. Participants with aSAH will: * Have a blood sample collected shortly after admission to hospital. * Undergo epigenome-wide DNA methylation profiling using the Infinium MethylationEPIC v2.0 BeadChip microarray. * Be monitored for the development of DIND, defined by clinical symptoms and radiographic vasospasm. This study aims to identify potential epigenetic biomarkers for aSAH susceptibility and DIND risk, which could improve early diagnosis and risk stratification in affected patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DNA methylation changes associated with aneurysmal subarachnoid hemorrhage and delayed ischemic neurologic deficit
Timeframe: Within four days following the enrollment (as blood samples will be collected within days 1-4 post-hemorrhage). Methylation profiling and CpG analysis the entire batch will be conducted within one year following enrollment of the last participant